- Home
- OI vs SLNO Comparison
OI vs SLNO Comparison
Compare OI & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- SLNO
- Stock Information
- Founded
- OI 1903
- SLNO 1999
- Country
- OI United States
- SLNO United States
- Employees
- OI N/A
- SLNO N/A
- Industry
- OI Containers/Packaging
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- OI Consumer Discretionary
- SLNO Health Care
- Exchange
- OI Nasdaq
- SLNO Nasdaq
- Market Cap
- OI 2.2B
- SLNO 3.8B
- IPO Year
- OI N/A
- SLNO 2014
- Fundamental
- Price
- OI $15.67
- SLNO $86.65
- Analyst Decision
- OI Buy
- SLNO Strong Buy
- Analyst Count
- OI 8
- SLNO 9
- Target Price
- OI $16.13
- SLNO $103.33
- AVG Volume (30 Days)
- OI 1.8M
- SLNO 1.1M
- Earning Date
- OI 07-29-2025
- SLNO 08-06-2025
- Dividend Yield
- OI N/A
- SLNO N/A
- EPS Growth
- OI N/A
- SLNO N/A
- EPS
- OI N/A
- SLNO N/A
- Revenue
- OI $6,505,000,000.00
- SLNO N/A
- Revenue This Year
- OI $1.90
- SLNO N/A
- Revenue Next Year
- OI $1.28
- SLNO N/A
- P/E Ratio
- OI N/A
- SLNO N/A
- Revenue Growth
- OI N/A
- SLNO N/A
- 52 Week Low
- OI $9.23
- SLNO $39.73
- 52 Week High
- OI $15.77
- SLNO $87.16
- Technical
- Relative Strength Index (RSI)
- OI 69.33
- SLNO 67.62
- Support Level
- OI $14.64
- SLNO $81.61
- Resistance Level
- OI $15.58
- SLNO $86.79
- Average True Range (ATR)
- OI 0.45
- SLNO 3.10
- MACD
- OI 0.11
- SLNO 0.33
- Stochastic Oscillator
- OI 95.78
- SLNO 95.37
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.